| name | es-cushing-lifelong-follow-up-carney-complex |
| description | This skill recommends lifelong follow-up tests for cardiac myxoma and associated disease (testicular tumors, acromegaly, thyroid lesions) in patients with Carney complex. Use when managing a Cushing’s syndrome patient with a confirmed or suspected Carney complex diagnosis (e.g., spotty skin lentigines, cardiac myxoma, endocrine tumors). |
Lifelong Follow-Up Tests for Cardiac Myxoma and Associated Disease in Patients With Carney Complex
STEP 1 — Gather Information
Confirm Carney complex diagnosis: obtain history of spotty skin pigmentation, cardiac myxoma, endocrine overactivity (e.g., Cushing’s syndrome, acromegaly), and family history; perform physical exam for lentigines, myxomas, testicular masses; review prior imaging and endocrine labs.
STEP 2 — Rule In / Rule Out
Is Carney complex confirmed or strongly suspected? If no, discontinue this pathway; if yes, proceed to stratification.
STEP 3 — Classify or Stratify
Determine which associated diseases to screen based on age, sex, and prior findings: all patients need cardiac myxoma surveillance; males add testicular tumor screening; all add acromegaly (IGF‑1) and thyroid lesion screening.
STEP 4 — Decide
Order lifelong surveillance: cardiac echocardiogram every 1–2 years, testicular ultrasound annually (males), serum IGF‑1 annually, thyroid ultrasound or TSH annually; refer abnormal results to cardiology, urology, or endocrinology.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on symptoms alone—cardiac myxoma can be asymptomatic until embolic event; do not skip screening because the patient feels well; avoid confusing isolated cardiac myxoma without systemic Carney complex features, which does not require the same lifelong multimodal surveillance.
Concrete Clinical Example
A 24‑year‑old man presents with Cushing’s syndrome due to primary pigmented nodular adrenal disease, spotty skin lentigines on lips, and a brother who died of cardiac myxoma at age 30; Carney complex is diagnosed, prompting initiation of annual echocardiogram, testicular ultrasound, IGF‑1, and thyroid ultrasound.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI:10.1210/jc.2015-1818
